PE20231504A1 - Anticuerpos especificos para kras y sus usos - Google Patents
Anticuerpos especificos para kras y sus usosInfo
- Publication number
- PE20231504A1 PE20231504A1 PE2022002496A PE2022002496A PE20231504A1 PE 20231504 A1 PE20231504 A1 PE 20231504A1 PE 2022002496 A PE2022002496 A PE 2022002496A PE 2022002496 A PE2022002496 A PE 2022002496A PE 20231504 A1 PE20231504 A1 PE 20231504A1
- Authority
- PE
- Peru
- Prior art keywords
- kras
- cdr
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G01N33/5758—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referida a un anticuerpo aislado o fragmento de union al antigeno de este que se une a KRas humano, en donde el anticuerpo se une especificamente al KRas unido a GDP (KRasGDP) con una mayor afinidad que al KRas unido a GTP (KRas-GTP), donde el anticuerpo comprende (a) una region variable de la cadena liviana que comprende: (i) CDR-L1 que comprende la secuencia de aminoacidos SGSSSNIGSNYVY (SEQ ID NO:9); (ii) CDR-L2 que comprende la secuencia de aminoacidos RNNQRPS (SEQ ID NO:10); (iii) CDR-L3 que comprende la secuencia de aminoacidos AAWDERLSGWV (SEQ ID NO:11); y (b) una region variable de la cadena pesada que comprende: (i) CDR-H1 que comprende la secuencia de aminoacidos SSNWWS (SEQ ID NO:12); (ii) CDR-H2 que comprende la secuencia de aminoacidos EIYHSGSTNYNPSLKS (SEQ ID NO:13); y (iii) CDR-H3 que comprende la secuencia de aminoacidos GSSSWYDLGPFDY (SEQ ID NO:14). Tambien se refiere a metodos para cribar inhibidores de KRas y metodos para medir la union de KRas a los anticuerpos descritos en la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018356P | 2020-04-30 | 2020-04-30 | |
| PCT/US2021/029517 WO2021222333A1 (en) | 2020-04-30 | 2021-04-28 | Kras specific antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231504A1 true PE20231504A1 (es) | 2023-09-26 |
Family
ID=75977821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002496A PE20231504A1 (es) | 2020-04-30 | 2021-04-28 | Anticuerpos especificos para kras y sus usos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220112308A1 (es) |
| EP (1) | EP4143237A1 (es) |
| JP (1) | JP2023524041A (es) |
| KR (1) | KR20230002598A (es) |
| CN (1) | CN115461375A (es) |
| AU (1) | AU2021263767A1 (es) |
| BR (1) | BR112022022021A2 (es) |
| CA (1) | CA3174692A1 (es) |
| CR (1) | CR20220598A (es) |
| IL (1) | IL297672A (es) |
| MX (1) | MX2022013310A (es) |
| PE (1) | PE20231504A1 (es) |
| TW (1) | TW202204420A (es) |
| WO (1) | WO2021222333A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119212994A (zh) | 2021-12-17 | 2024-12-27 | 建新公司 | 作为shp2抑制剂的吡唑并吡嗪化合物 |
| IL314606A (en) * | 2022-02-07 | 2024-09-01 | Genentech Inc | Solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2- (((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| IL317823A (en) * | 2022-06-30 | 2025-02-01 | Lilly Co Eli | KRAS G12C inhibitor for cancer treatment |
| CN116640218B (zh) * | 2023-06-01 | 2024-06-04 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种靶向kras g12v单链抗体片段、嵌合抗原受体car及应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025212580A1 (en) * | 2024-04-01 | 2025-10-09 | Xdc Precision Therapeutics Llc | Antibody-kras binder conjugates, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE337223B (es) | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| DE2031216A1 (de) | 1969-06-19 | 1971-01-14 | Citizen Watch Co Ltd , Tokio | Tag und Datum Stellvorrichtung fur Uhren mit Kalender |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6248537B1 (en) * | 1999-05-28 | 2001-06-19 | Institut Pasteur | Use of the combing process for the identification of DNA origins of replication |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| PH12013500974A1 (en) * | 2010-11-17 | 2013-07-08 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| KR101602876B1 (ko) * | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) * | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2018069871A2 (en) * | 2016-10-13 | 2018-04-19 | Sorrento Therapeutics, Inc. | Anti-kras binding proteins |
| MX392368B (es) * | 2016-12-15 | 2025-03-24 | Univ California | Composiciones y metodos para el tratamiento del cancer |
| US20200339681A1 (en) * | 2017-11-16 | 2020-10-29 | Orum Therapeutics Inc. | Antibody inhibiting activated ras in cell by internalizing into cytosol of cell, and use thereof |
-
2021
- 2021-04-28 CN CN202180031399.8A patent/CN115461375A/zh active Pending
- 2021-04-28 KR KR1020227039081A patent/KR20230002598A/ko not_active Withdrawn
- 2021-04-28 AU AU2021263767A patent/AU2021263767A1/en not_active Abandoned
- 2021-04-28 JP JP2022566072A patent/JP2023524041A/ja active Pending
- 2021-04-28 PE PE2022002496A patent/PE20231504A1/es unknown
- 2021-04-28 CA CA3174692A patent/CA3174692A1/en active Pending
- 2021-04-28 WO PCT/US2021/029517 patent/WO2021222333A1/en not_active Ceased
- 2021-04-28 BR BR112022022021A patent/BR112022022021A2/pt not_active Application Discontinuation
- 2021-04-28 CR CR20220598A patent/CR20220598A/es unknown
- 2021-04-28 IL IL297672A patent/IL297672A/en unknown
- 2021-04-28 US US17/243,129 patent/US20220112308A1/en active Pending
- 2021-04-28 EP EP21726496.9A patent/EP4143237A1/en active Pending
- 2021-04-28 TW TW110115400A patent/TW202204420A/zh unknown
- 2021-04-28 MX MX2022013310A patent/MX2022013310A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220598A (es) | 2023-01-17 |
| JP2023524041A (ja) | 2023-06-08 |
| TW202204420A (zh) | 2022-02-01 |
| KR20230002598A (ko) | 2023-01-05 |
| AU2021263767A1 (en) | 2022-09-08 |
| US20220112308A1 (en) | 2022-04-14 |
| WO2021222333A1 (en) | 2021-11-04 |
| IL297672A (en) | 2022-12-01 |
| CN115461375A (zh) | 2022-12-09 |
| EP4143237A1 (en) | 2023-03-08 |
| MX2022013310A (es) | 2022-11-14 |
| BR112022022021A2 (pt) | 2022-12-13 |
| CA3174692A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| ES2523740T3 (es) | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 | |
| PE20211709A1 (es) | Anticuerpos que reconocen tau | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| CU20210073A7 (es) | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| NZ596042A (en) | Humanized anti-factor d antibodies | |
| NZ585559A (en) | Humanized antibodies against tl1a | |
| CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
| MX2018014714A (es) | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. | |
| MX2024012479A (es) | Anticuerpos anti-tl1a y metodos de uso de los mismos | |
| PE20121817A1 (es) | Anticuerpos antagonistas anti-notch3 | |
| MX338694B (es) | Composiciones y metodos para el diagnostico y el tratamiento de tumores. | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| PE20231680A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| RU2018106456A (ru) | Антитело к epha4 | |
| PE20230414A1 (es) | Agentes de fijacion a tie2 y metodos de uso | |
| AR124558A1 (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| PE20231953A1 (es) | Anticuerpos multiespecificos y combinaciones de anticuerpos | |
| AR126009A1 (es) | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam | |
| WO2022174103A3 (en) | Monoclonal antibodies specific for human ror1 | |
| RU2021128024A (ru) | Способы культивирования клеток |